Edgewise Therapeutics
EWTX · NASDAQ
$39.75+$1.83 (+4.83%)TodayMarket closed ·
Prev close $37.92
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 6.5% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- $1.90
- Revenue estimate
- $119.23M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.4794 | -$0.53 | −10.6% |
| Q1 FY26 | -$0.4964 | -$0.46 | +7.3% |
| Q4 FY25 | -$0.4445 | -$0.47 | −5.7% |
| Q3 FY25 | -$0.4055 | -$0.39 | +3.8% |
| Q2 FY25 | -$0.4238 | -$0.34 | +19.8% |
| Q1 FY25 | -$0.4376 | -$0.43 | +1.7% |
| Q4 FY24 | -$0.425 | -$0.42 | +1.2% |
| Q3 FY24 | -$0.3789 | -$0.36 | +5.0% |
Earnings calls
- Special Call - Edgewise Therapeutics, Inc.
- Special Call - Edgewise Therapeutics, Inc.
- 44th Annual J.P. Morgan Healthcare Conference
- Piper Sandler 37th Annual Healthcare Conference
- Special Call - Edgewise Therapeutics, Inc.
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- Special Call - Edgewise Therapeutics, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.